CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
The draft policy would continue to provide coverage for surveillance testing for kidney, heart, and lung transplant patients without a tie to protocol biopsy, underscoring the value of this important non-invasive molecular testing for solid organ transplant patients.
In addition, the draft policy introduces a bundled payment concept for surveillance testing. The Company is reviewing the draft coverage and payment policy and anticipates providing additional information during its upcoming earnings call on August 6, 2025.
'We believe publication of this draft policy solidifies coverage for surveillance testing and supports our longstanding position that our tests improve health outcomes for transplant patients,' said John W. Hanna, President and CEO of CareDx. 'We do not expect changes in the use of our testing in response to this draft LCD and remain deeply committed to patient care and providing access to our testing. We look forward to providing feedback on the draft LCD through the public comment process.'
The proposed LCD is available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40059&ver=8&contractorName=all&contractorNumber=all&updatePeriod=1156&sortBy=updated&bc=13
About CareDx – The Transplant Company™
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statement
This press release includes forward-looking statements, including statements regarding the potential benefits and results that may be achieved with AlloSure ®, AlloMap ® and HeartCare ®, the use of our tests, and reimbursement coverage. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx's filings with the Securities and Exchange Commission (the 'SEC'), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
HSBC Trims Amgen (AMGN) Price Target, Maintains Buy Rating
Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc. (NASDAQ:AMGN) from $385 to $357 while reiterating a Buy rating, as concerns mount over potential earnings pressure tied to proposed U.S. trade policies. The firm's updated valuation reflects a more cautious outlook amid geopolitical uncertainty and the possibility of new tariffs on pharmaceutical imports. A pharmacist filling a prescription for a complex drug developed by the company. In a research note to clients, HSBC warned that a 25% U.S. tariff on certain pharmaceutical products could reduce earnings for companies like Amgen Inc. (NASDAQ:AMGN) by as much as 6% to 14%, depending on the final structure of the policy. While details remain fluid, analysts are increasingly factoring in trade-related headwinds as part of broader risk assessments across the healthcare sector. Beyond direct tariff exposure, HSBC also highlighted the potential for indirect financial impacts, including shifts in effective tax rates. These changes could further complicate earnings forecasts and weigh on investor sentiment heading into the second half of the year. Despite the lowered target, HSBC maintained a positive long-term view on Amgen, citing the company's robust pipeline and diversified portfolio of oncology, inflammation, and rare disease therapies. However, the firm acknowledged that near-term macro risks may cloud what has otherwise been a solid year for the biotech giant. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
9 minutes ago
- Yahoo
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating
Royalty Pharma plc (NASDAQ:RPRX) is one of the high-margin pharma stocks to buy now. Royalty Pharma plc (NASDAQ:RPRX) received a vote of confidence from Morgan Stanley this week as analyst Terence Flynn raised the firm's price target to $54 from $51 while maintaining an Overweight rating. The adjustment reflects a favorable outlook on the company's cash flow durability and its ability to weather broader industry headwinds. A scientist in a laboratory looking through a microscope, surrounded by petri dishes and beakers while researching new biopharmaceutical advances. Flynn noted in a client note that large-cap pharmaceutical and biotech names have struggled to gain traction this year, weighed down by macroeconomic pressures and lingering regulatory uncertainty. Challenges such as evolving drug pricing frameworks, international tariff exposure, and ongoing personnel shifts within the FDA have all contributed to investor caution across the healthcare space. Despite this backdrop, Royalty Pharma continues to distinguish itself through its unique business model, which centers on acquiring royalty streams tied to established and emerging therapies. The company's portfolio, anchored by revenue from blockbuster drugs such as Tysabri, Imbruvica, and Trelegy, has offered a more stable earnings profile than many of its industry peers. Flynn's upward revision suggests Royalty Pharma remains well-positioned in a sector facing ongoing volatility, with defensive qualities that appeal to investors seeking income and resilience in a complex policy and economic environment. While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the high-margin pharma stocks to buy now. Morgan Stanley has lowered its price target on United Therapeutics (NASDAQ: UTHR) to $328 from $348, while maintaining an Equal Weight rating, amid broader headwinds facing the biotech and pharmaceutical sectors. The firm flagged persistent macroeconomic challenges and regulatory uncertainties that continue to weigh on investor sentiment across the space. A team of scientists in a laboratory, running tests on a biotechnology product. In a research note to clients, the firm pointed to several factors pressuring large-cap healthcare names this year, including policy volatility around drug pricing, ongoing debates over international transfer pricing, and staffing turnover at the FDA. Against that backdrop, United Therapeutics is facing specific questions about near-term sales performance, particularly around its key pulmonary arterial hypertension therapy, Tyvaso. Morgan Stanley is now modeling second-quarter Tyvaso sales of $442 million, below the Street consensus of $483 million. Total revenue is expected to reach $768 million, also under consensus estimates of $805 million. The firm attributes the cautious outlook to potential softness in Tyvaso DPI uptake and less momentum in patient onboarding than previously projected. Despite strong fundamentals and long-term growth driver, including its organ manufacturing pipeline, Morgan Stanley appears to be taking a more conservative stance in the near term. With shares already reflecting much of the upside potential, the firm sees a more balanced risk-reward profile at current levels. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey.
